Beijing Yiling

Yiling Pharmaceutical is a leading Chinese pharmaceutical group specializing in the modernization of Traditional Chinese Medicine (TCM) and the development of innovative chemical drugs. Founded by Academician Wu Yiling, the company operates based on the "Collateral Disease Theory" (Luobing), a unique medical framework that guides its R&D in cardiovascular, respiratory, and metabolic diseases. Its flagship product, Lianhua Qingwen, gained international prominence as a treatment for respiratory viral infections, including influenza and COVID-19. The company maintains a robust integrated industrial chain encompassing medicinal herb cultivation, advanced R&D, and large-scale GMP manufacturing. Yiling is increasingly expanding its pipeline into chemical drugs and biologics, targeting oncology and neurology while maintaining its leadership in the TCM sector.